Partially in line with this, low FBXL7 mRNA expression indicates poor survival in patients with pancreatic and prostatic cancers; this low expression can also facilitate the invasion of pancreatic and prostatic cancers [34]. This evidence concerns the gene FBXL7 and prostate carcinoma.